Skip to main content
. 2023 Jun 22;2023(6):CD001423. doi: 10.1002/14651858.CD001423.pub4

Gabric 1987.

Methods Multisite study
Randomization: unclear
Blinding: participants, providers
Participants Geographic region: Croatia
Study setting: community
N = 30
Baseline IPSS: NR
Baseline prostate volume: NR
Mean age (range): 65 (40 to 82) years
Race: white
Diagnostic criteria: BPH, stages I, II (Vahlensieck)
Interventions Control: placebo
Treatment: Prostagutt forte (SR + Urtica dioica) 20 drops 3 times daily
Study duration: 6 weeks
Lost to follow‐up: none
Outcomes Physician rating of improvement
Peak urine flow
Bladder residual volume
Dropouts due to side effects: none
Notes Exclusions: stage IV prostate adenoma, bacterial prostatitis, cystitis, urethritis
Full text not available for this update.